undefined (TENX) 가격

Tenax Therapeutics plunges 85% as Phase 3 trial misses endpoints

Tenax Therapeutics' Phase 3 LEVEL trial of TNX-103 missed its primary endpoint in PH-HFpEF, erasing about 85 percent of shareholder value.